Document:

Exhibit 10.2 - Assignment Agreement to the Option Agreement

                ASSIGNMENT AGREEMENT TO THE OPTION AGREEMENT

   This Assignment Agreement (the "Assignment"), effective on July 31, 2008
(hereinafter the "Effective Date"), is made by and between THE PENN STATE
RESEARCH. FOUNDATION, a non-profit corporation duly organized and existing
under the laws of the Commonwealth of Pennsylvania and having an office at
304 Old Main, University Park, Pennsylvania 16802 (hereinafter referred to
as "PSRF"), Northwest Medical Research Inc., having its principal office at
#90 NW Second Street, P.O. Box 910, Stevenson, Washington. 98648
(hereinafter referred to as "OPTIONEE") and Generic Marketing Services,
Inc., a publicly traded corporation controlled by Dr. Marvin Hausman
(hereinafter "NEWCO").

   WHEREAS, PSRF and OPTIONEE entered into an Option Agreement ("Option
Agreement"), effective May 1, 2006, granting OPTIONEE an option to obtain an
exclusive license under the PATENTS RIGHTS to make, have made, use and sell
LICENSED PRODUCTS and to perform processes covered thereby.

   WHEREAS, Paragraph 11.1 of the Option Agreement permits the assignment of
this Option Agreement to another entity formed and controlled by Dr. Marvin
Hausman, President of Northwest Medical Research Inc.

   WHEREAS, OPTIONEE has represented that it wishes to assign its exclusive
option rights to the INVENTION and LICENSED PATENTS as covered in the Option
Agreement;

   WHEREAS, PSRF desires to have the INVENTION and LICENSED PATENTS utilized
in the public interest and is willing to assign PSRF's rights hereunder to
NEWCO (as hereinafter defined),

   Now, therefore, in consideration for the foregoing and the covenants and
promises hereinafter set forth, and with intent to be legally bound, the
parties hereto agree as follows:

1. NEWCO hereby agrees to undertake all terms, conditions and obligations of
OPTIONEE under- the May 1, 2006 Option Agreement entered into by and between
PSRF and OPTIONEE, a copy of which is attached hereto as Appendix A. All
capitalized terms used without definition in this Assignment Agreement shall
have the meanings set forth in the Option Agreement.

2. PSRF has been provided with adequate notice and information regarding
OPTIONEE'S acquisition of NEWCO, and agrees that said acquisition conforms
to the terms of Article XI of the Option Agreement.

3. All parties agree that NEWCO is obligated to reimburse PSRF for
previously unreimbursed and fixture patent expenses under Article VII of the
Option Agreement. The current unreimbursed amount is approximately one
thousand, six hundred and fifty nine dollars and fifty cents [$1,659.50]
(for expenses through July 15, 2008) and shall be due and payable upon
execution of this Assignment Agreement.

4. Paragraph 1.10 is added to the Option Agreement as follows:

<PAGE>

   1.10   NEWCO shall mean Generic Marketing Service, Inc. having a legal
address of 2811 Reidville Road, Spartanburg, SC 29301, of which Dr. Marvin
Hausman has voting control of NEWCO.

5. Paragraph 3.2 of the Option Agreement is modified as follows:

   3.2   Term. The term of the exclusive option of Paragraph 2.1 hereinabove
shall begin upon the Effective Date and expire March 15, 2010 (hereinafter
"Option Period"), so long as OPTIONEE, and the assignee, NEWCO, comply with
the terms of this Option Agreement.

   All other terms and conditions of the Option Agreement shall remain
unchanged.

   IN WITNESS WHEREOF, the parties hereto have executed this Assignment
Agreement, in duplicate, by proper persons thereunto duly authorized.

THE PENN STATE RESEARCH FOUNDATION

By:    /s/ David E. Branigan
       ------------------------

Name:  David E. Branigan
       ------------------------

Title: Treasurer
       ------------------------

Date:  AUG 26 2008
       ------------------------

GENERIC MARKETING SERVICES

By:    /s/ Frank Arnone
       ------------------------

Name:  Frank Arnone
       ------------------------

Title: C.E.O.
       ------------------------

Date:  7/28/08
       ------------------------

NORTHWEST MEDICAL RESEARCH INC. By:

By:    /s/ Marvin S. Hausman
       ------------------------

Name:  Marvin S. Hausman MD
       ------------------------

Title: President
       ------------------------

Date:  7/31/08
       ------------------------

Ipo-mds/Addendum/NorthwestMedResearch

<PAGE>Exhibit 10.3   Assignment and Assumption Agreement

                    ASSIGNMENT AND ASSUMPTION AGREEMENT

   This Assignment and Assumption Agreement (the "Assignment"), effective on
July 31, 2008 (the "Effective Date"), is made by and between Northwest
Medical Research, Inc., having its principal office at  #90 NW Second Street,
P.O. Box 910, Stevenson, Washington 98648 ("NW MED") and Generic Marketing
Services, Inc., a publicly traded corporation controlled by Dr. Marvin
Hausman ("NEWCO").

   NW MED entered into an Option Agreement (the "Option Agreement"),
effective May 1, 2006, with The Penn State Research Foundation ("PSRF")
granting NW MED an option to license from PSRF certain intellectual property
and know-how, patent applications, any continuations, divisional applications
and any patents issuing therefrom (the "Licensed Patents") for the purpose of
developing and commercializing certain Licensed Products, as such terms are
defined under the Option Agreement.

   The provisional patent application included in the Licensed Patents was
entitled "Identification of Selenoergothioneine as a Natural Organic Form of
Selenium from Cultivated Mushrooms", U.S. Provisional Patent Application No.
60/782,204, filed on March 14, 2006 and naming R. Beelman, J. Dubost, D.
Peterson and M. Hausman as co-inventors (the "Original Provisional Patent
Application").  The Original Provisional Patent Application served as a
priority for U.S. Patent Application Serial No. 11/686,033, filed on March
14, 2007 and entitled "Phytonutrient Compositions from Mushrooms or
Filamentous Fungi and Methods of Use" and related Patent Cooperation Treaty
("PCT") patent application PCT U.S.07/63984 filed on March 14, 2007 (the
"Patent Applications"; the Original Provisional Patent Application, together
with the Patent Applications and any future related continuations,
divisionals and national phase applications, as well as all related know-how
and good will, referred to herein as the "Licensed Patents").

   In connection with the Option Agreement, NW MED has reimbursed and paid
certain patent prosecution expenses relating to the Licensed Patents, and
Paragraph 11.1 of the Option Agreement permits the assignment of the Option
Agreement in certain circumstances.

   NW MED wishes to assign to NEWCO its exclusive option rights under the
Option Agreement and to the Licensed Patents as covered in the Option
Agreement, and NEWCO desires to assume the obligations of NW MED under the
Option Agreement, in consideration for the issuance of 3,500,000 shares of
NEWCO's common stock;

   In consideration for the foregoing and the covenants and promises
hereinafter set forth, and with intent to be legally bound, the parties
hereto agree as follows:

   1.  NW MED hereby assigns to NEWCO all of its right, title and interest
under the Option Agreement and to the Licensed Patents, together with all
other know how and goodwill of NW MED not specifically covered by the Option
Agreement or the Licensed Patents but relating to the subject matter of the
Licensed Patents, and NEWCO hereby assumes all of the obligations of NW MED
under the Option Agreement.

   2.  In consideration therefor, NEWCO shall issue to NW MED 3,500,000
shares of its common stock (the "Shares"), which Shares, when issued shall be
duly and validly issued, fully paid and non assessable shares of common stock
of NEWCO.  NEWCO represents and warrants that all corporate action necessary
to authorize the issuance of the Shares and the execution and delivery of
this Agreement has been duly taken, and does not violate the Certificate of
Incorporation, Bylaws, or any contract or obligation to which it is a party.
NW MED represents and warrants that all corporate action necessary to
authorize the execution and delivery of this Agreement has been duly taken,
and does not violate the Certificate of Incorporation, Bylaws, or any
contract or obligation to which it is a party, that the Option Agreement
currently is in full force and effect, and that it will be acquiring the
Shares for investment purposes only and not for distribution.

   3.  The assignment and assumption hereunder and the obligation of NEWCO to
issue the Shares to NW MED is subject to the approval by PSRF to the
assignment and assumption of the Option Agreement in accordance with the
provisions of Paragraph 11.1 of the Option Agreement.  NEWCO acknowledges
receipt of a true and correct copy of the Option Agreement.

   4.  The parties agree to execute and deliver all further documents and
instruments necessary to effect the assignment and assumption set forth in
this Agreement.

   5.  This Agreement may be executed in counterparts, which when taken
together, shall constitute one and the same instrument.

   IN WITNESS WHEREOF, the parties hereto have executed this Assignment and
Assumption Agreement, by proper persons thereunto duly authorized.

NORTHWEST MEDICAL RESEARCH, INC.

By:    /s/ Marvin S. Hausman
       ------------------------

Name:  Marvin S. Hausman MD
       ------------------------

Title: President
       ------------------------

GENERIC MARKETING SERVICES, INC.

By:    /s/ Frank Arnone
       ------------------------

Name:  Frank Arnone
       ------------------------

Title: C.E.O.
       ------------------------

<PAGE>exhibit10-10aug22008.htm

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
10.10

    

    

    CHARMING
SHOPPES, INC.

    2004
STOCK AWARD AND INCENTIVE PLAN

    STOCK
APPRECIATION RIGHTS AGREEMENT

     

    Agreement
dated as of July 16, 2008 (the “Grant Date”) between CHARMING SHOPPES, INC. (the
“Company”) and Alan Rosskamm (the “Rosskamm”).

     

    

     

    1.    Grant of SAR; Consideration;
Rosskamm Acknowledgments.

     

    The
Company hereby confirms the grant, under the Company’s 2004 Stock Award and
Incentive Plan (the “Plan”), to Rosskamm on the Grant Date of a stock
appreciation right (the “SAR”) with respect to 41,152 shares of the Company’s
common stock, par value $.10 per share (the “Shares”).  The SAR
represents the right to receive, at exercise, a number of Shares with a then
Fair Market Value equal to the appreciation in value of the Shares over the base
amount.  The base amount is $4.60 per share, which is the fair market
value of a Share on the Grant Date (the “Base Amount”).

     

    Rosskamm
shall be required to pay no consideration for the grant of the SAR except for
his agreement to provide services to the Company prior to exercise and his
agreement to abide by the terms set forth in the Plan, this Stock Appreciation
Rights Agreement (the “Agreement”), and any Rules and Regulations under the
Plan.  Rosskamm acknowledges and agrees that (i) the SAR is
nontransferable, except as provided in Sections 8 and 9 hereof and in the Plan,
(ii) the SAR is subject to forfeiture in certain circumstances, as specified in
Section 7 hereof, and (iii) sales of Shares will be subject to the Company’s
policies regulating trading by employees, including any applicable “blackout” or
other designated periods in which sales of Shares are not
permitted.

     

    

     

    2.    Incorporation of Plan by
Reference.

     

     
The SAR has been granted to Rosskamm under the Plan.  All of the
terms, conditions and other provisions of the Plan are hereby incorporated by
reference into this Agreement.  Capitalized terms used in this
Agreement but not defined herein shall have the same meanings as in the
Plan.  If there is any conflict between the provisions of this
Agreement and the provisions of the Plan, the provisions of the Plan shall
govern.  Rosskamm hereby accepts the grant of the SAR, acknowledges
receipt of the Plan, and agrees to be bound by all the terms and provisions
hereof and thereof (as presently in effect or hereafter amended), and by all
decisions and determinations of the Board or Committee under the
Plan.

     

    
      
        
           

        

         

      

      
        1

        
          

        

      

      
         

      

    

    

     

    3.     Date When
Exercisable.

     

    (a) This SAR
may be exercised only if and to the extent that it has become exercisable as
specified in this Agreement.  Subject to the terms and conditions of
this Agreement and the approval of the SAR by the Committee, this SAR shall vest
and become exercisable in full on the earlier to occur of the
following:  (i) on the date that the first permanent Chief Executive
Officer immedietely succeeding Dorrit J. Bern, the Company’s former Chief
Executive Officer, commences employment, (ii) upon a Change of Control as
provided in Section 6, (iii) upon Rosskamm’s death, or (iv) upon termination of
Rosskamm’s service as a Director of the Company due to disability.

    

    (b) The SAR
shall expire at 5:00 p.m. on the day before the seventh anniversary of the Grant
Date, unless the SAR terminates on an earlier date as provided
herein.

     

    

     

    4.     Method of
Exercise.

     

    (a) The SAR
may be exercised, to the extent the SAR is then vested and exercisable, by
delivery to and receipt by the Secretary of the Company at 3750 State Road,
Bensalem, Pennsylvania 19020, of a written notice, signed by Rosskamm,
specifying the portion of the vested SAR that Rosskamm wishes to
exercise.  Simultaneous with or as soon as practicable after the
receipt of such notice, the Company shall deliver to Rosskamm a number of whole
Shares that will be determined by dividing the Stock Appreciation by the Fair
Market Value of a Share on the date of exercise, less applicable tax
withholding.  “Stock Appreciation” shall mean the amount that results
from multiplying (i) the number of Shares as to which the SAR is exercised by
(ii) the amount by which the Fair Market Value of a Share on the date of
exercise exceeds the Base Amount.  Only whole Shares will be delivered
pursuant to the exercise of the SAR.

     

    (b) Upon
exercise of the SAR, the Company will deliver a stock certificate for the Shares
to be delivered, with any requisite legend affixed.  Such exercise may
include instructions to the Company to deliver Shares due upon exercise of the
SAR to any registered broker or dealer designated by the Committee in lieu of
delivery to Rosskamm.  Such instructions must designate the account
into which the Shares are to be deposited.  The method of exercise and
related matters governed by this Section 4 shall be subject to Rules and
Regulations adopted by the Committee and in effect at the time Rosskamm’s notice
of exercise is received by the Company; such Rules and Regulations may vary from
or limit the procedures specified in this Section 4, and may specify other
methods of exercise.  Upon exercise of any portion of the SAR, the
exercised portion of the SAR shall terminate and cease to be
outstanding.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (c) If, on
the date on which the vested SAR will terminate according to its terms, the
Executive has not given the Company written notice of exercise, and if the Stock
Appreciation amount is a positive number, then the outstanding vested portion of
the SAR shall be automatically exercised and taxes shall be withheld as
described in Section 5 below.

     

    

     

    5.    Tax
Withholding.

     

    Unless
otherwise determined by the Company upon notice to Rosskamm, the Company will
withhold from the Shares to be delivered upon the exercise of the SAR a
sufficient number of such Shares to satisfy the minimum federal, state and local
tax withholding obligations relating to the SAR exercise.  The Shares
withheld will be valued at the Fair Market Value, determined in such manner as
may be specified under the Plan.

     

    

     

    6.    Change of Control
Provisions.

     

    (a) Acceleration of
Exercisability.  In the event of a Change of Control at a time
when Rosskamm is employed by the Company or any of its subsidiaries or is
serving as a Director of the Company, this SAR shall become immediately and
fully vested and exercisable immediately prior to the occurrence of such Change
of Control.

     

    (b) Exercise after a Change in
Control; Adjustments.  In the event of Rosskamm’s termination
of employment after a Change in Control, or in the event that Rosskamm ceases to
be a Director of the Company after a Change of Control, the vested SAR, to the
extent then outstanding, shall be exercisable for a one year period from the
later of (i) the date of such termination, or (ii) the date of such cessation,
as the case may be. In the event of a Change in Control, the Committee may make
such adjustments and take such other actions with respect to outstanding SARs as
the Committee deems appropriate pursuant to Section 10(c) of the
Plan.

     

    (c) Definitions of Certain
Terms.  For purposes of this Agreement, the following
definitions shall apply:

     

    (i) “Beneficial Owner,”
“Beneficially Owns,” and “Beneficial Ownership” shall have the meanings ascribed
to such terms for purposes of Section 13(d) of the Exchange Act and the rules
thereunder, except that, for purposes of this Section 6, “Beneficial Ownership”
(and the related terms) shall include Voting Securities that a Person has the
right to acquire pursuant to any agreement, or upon exercise of conversion
rights, warrants, options or otherwise, regardless of whether any such right is
exercisable within 60 days of the date as of which Beneficial Ownership is to be
determined.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (ii) “Change of Control” means and
shall be deemed to have occurred if

     

    (1) any
Person, other than the Company or a Related Party, acquires directly or
indirectly the Beneficial Ownership of any Voting Security of the Company and
immediately after such acquisition such Person has, directly or indirectly, the
Beneficial Ownership of Voting Securities representing 20 percent or more of the
total voting power of all the then-outstanding Voting Securities;
or

     

    (2) those
individuals who as of the Grant Date constitute the Board or who thereafter are
elected to the Board and whose election, or nomination for election, to the
Board was approved by a vote of at least two-thirds (2/3) of the directors then
still in office who either were directors as of the Grant Date or whose election
or nomination for election was previously so approved, cease for any reason to
constitute a majority of the members of the Board; or

     

    (3) there is
consummated a merger, consolidation, recapitalization or reorganization of the
Company, a reverse stock split of outstanding Voting Securities, or an
acquisition of securities or assets by the Company (a “Transaction”), other than
a Transaction which would result in the holders of Voting Securities having at
least 80 percent of the total voting power represented by the Voting Securities
outstanding immediately prior thereto continuing to hold Voting Securities or
voting securities of the surviving entity having at least 60 percent of the
total voting power represented by the Voting Securities or the voting securities
of such surviving entity outstanding immediately after such Transaction and in
or as a result of which the voting rights of each Voting Security relative to
the voting rights of all other Voting Securities are not altered;
or

     

    (4) there is
implemented or consummated a plan of complete liquidation of the Company or sale
or disposition by the Company of all or substantially all of the Company’s
assets other than any such transaction which would result in Related Parties
owning or acquiring more than 50 percent of the assets owned by the Company
immediately prior to the transaction.

     

    (iii) “Person” shall have the
meaning ascribed for purposes of Section 13(d) of the Exchange Act and the rules
thereunder.

     

    (iv) “Related Party” means (A) a
majority-owned subsidiary of the Company; or (B) a trustee or other fiduciary
holding securities under an employee benefit plan of the Company or any
majority-owned subsidiary of the Company; or (C) a corporation owned directly or
indirectly by the shareholders of the Company in substantially the same
proportion as their ownership of Voting Securities.  Additionally, a
Person would be considered a Related Party, if, prior to any acquisition of a
Voting Security which would result in any Person Beneficially Owning more than
ten percent of any outstanding class of Voting Security and which would be
required to be reported on a Schedule 13D or an amendment thereto, the Board
approved the initial transaction giving rise to an increase in Beneficial
Ownership in excess of ten percent and any subsequent transaction giving rise to
any further increase in Beneficial Ownership; provided, however, that such
Person has not, prior to obtaining Board approval of any such
transaction,

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    publicly
announced an intention to take actions which, if consummated or successful (at a
time such Person has not been deemed a “Related Party”), would constitute a
Change of Control.

     

    (v) “Voting Securities” means any
securities of the Company which carry the right to vote generally in the
election of directors.

     

    7.    Termination of Employment;
Cessation of Service as a Director

     

    This SAR
shall terminate and no longer be exercisable at the earlier of (i) the scheduled
expiration time of the SAR, as set forth in Section 3(b) above, or (ii) the
expiration of a one year period after Rosskamm ceases to be both a Director and
employee of the Company whether by reason of voluntary termination, involuntary
termination (other than for cause) or removal (other than for cause), if the SAR
granted to him will have already vested and become exercisable pursuant to
Section 3(a)(i) hereof at the time of such cessation, or the date of such
cessation if the SAR granted to him has not already vested and become
exercisable at the time of such cessation, or (iii) the expiration of a one year
period after Mr. Rosskamm ceases to be both a Director and employee of the
Company by reason of death or disability.

     

    

     

    8.    Limits on Transfer of SARs;
Beneficiaries.

     

    No right
or interest of a participant in this SAR shall be pledged, encumbered or
hypothecated to or in favor of any third party or shall be subject to any lien,
obligation or liability of Rosskamm to any third party.  This SAR
shall not be transferable to any third party by Rosskamm otherwise than by will
or the laws of descent and distribution, and this SAR shall be exercisable,
during the lifetime of Rosskamm, only by Rosskamm; provided, however, that
Rosskamm will be entitled to designate a beneficiary or beneficiaries to
exercise his rights under this SAR upon the death of Rosskamm, in the manner and
to the extent permitted by the Committee under Rules and Regulations adopted by
the Committee under the Plan, and the Committee may permit transfers otherwise
to the extent permitted under the Plan.

     

    

     

    9.    Investment
Representation.

     

    Unless,
at the time of any exercise of this SAR, the issuance and delivery of Shares
hereunder to Rosskamm is registered under a then-effective registration
statement under the Securities Act of 1933, as amended (the “Securities Act”),
and complies with all applicable registration requirements under state
securities laws, Rosskamm shall provide to the Company, as a condition to the
valid exercise of this SAR and the delivery of any certificates representing
Shares, appropriate evidence, satisfactory in form and substance to the Company,
that he is acquiring the Shares for investment and not with a view to the
distribution of the Shares or any interest in the Shares, and a representation
to the effect that Rosskamm shall make no sale or other disposition of the
Shares unless (i) the Company shall have received an opinion of counsel
satisfactory to it in form and substance that such sale or other disposition may
be made without registration under the then-applicable provisions of the
Securities Act, the related rules and

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    regulations
of the Securities and Exchange Commission, and applicable state securities laws
and regulations, or (ii) the sale or other disposition of the Shares shall be
registered under a currently effective registration statement under the
Securities Act and complies with all applicable registration requirements under
state securities laws.  The certificates representing the Shares may
bear an appropriate legend giving notice of the foregoing restriction on
transfer of the Shares, and any other restrictive legend deemed necessary or
appropriate by the Committee.

     

    

     

    10.    Miscellaneous.

     

    This
Agreement shall be binding upon the heirs, executors, administrators and
successors of the parties.  This Agreement constitutes the entire
agreement between the parties with respect to the SAR, and supersedes any prior
agreements or documents with respect to the SAR.  No amendment,
alteration, suspension, discontinuation or termination of this Agreement which
may impose any additional obligation upon the Company or impair the rights of
Rosskamm with respect to the SAR shall be valid unless in each instance such
amendment, alteration, suspension, discontinuation or termination is expressed
in a written instrument duly executed in the name and on behalf of the Company
and by Rosskamm.

     

    

     

    
      	
              CHARMING
      SHOPPES, INC.

            
	 
      
	 
      
	 
      
	
              BY:________________________________

            
	
              Colin
      D. Stern, Secretary

            
	 
      
	 
      
	
              EMPLOYEE:

            
	 
      
	 
      
	 
      
	
              ____________________________________

            
	
              Alan
      Rosskamm

            

    

    

     

    

     

    

     

    
      
         

      

      
        6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]